Your email has been successfully added to our mailing list.

×
0 0.00204498977505112 0.00204498977505112 0.00204498977505112 0.00204498977505112 0.00580777096114526 0.00584867075664625 0.00646216768916161
Stock impact report

AbCellera-Discovered Bamlanivimab Together With Etesevimab Authorized As The First And Only Antibody Therapy For Emergency Use In COVID-19 Patients Under The Age Of 12 [TheStreet.com]

Eli Lilly and Company (LLY) 
Last eli lilly and company earnings: 4/23 06:25 am Check Earnings Report
US:NYSE Investor Relations: investor.lilly.com
Company Research Source: TheStreet.com
Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together to include pediatric patients under the age of 12, including neonates (infants The expanded EUA is based on data from the BLAZE-1 Phase 2/3 clinical trial studying bamlanivimab and etesevimab administered together for the treatment of pediatric and infant patients with mild to moderate COVID-19 and who are at high risk for severe disease progression. The median time to complete symptom resolution as recorded in a trial specific daily symptom diary was 7 days for subjects treated with bamlanivimab 700 mg and etesevimab 1,400 mg and 5 days for subjects treated with weight-based dosing of bamlanivimab and etesevimab. No subject died or required hospitalization due to COVID-19. Pseudovirus and authentic virus studies conducted by AbCellera's partner, Eli Lilly and Company (Lilly), demonstrate that bamlanivimab and etesevimab together retain neutral Show less Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for LLY alerts
Opt-in for
LLY alerts

from News Quantified
Opt-in for
LLY alerts

from News Quantified